EN | RU
EN | RU

Help Support

Back

Ketorolac versus Meperidine: ED treatment of severe musculoskeletal low back pain

Ketorolac versus Meperidine: ED treatment of severe musculoskeletal low back pain Ketorolac versus Meperidine: ED treatment of severe musculoskeletal low back pain
Ketorolac versus Meperidine: ED treatment of severe musculoskeletal low back pain Ketorolac versus Meperidine: ED treatment of severe musculoskeletal low back pain

The study objective was to assess the efficacy and patient acceptance of ketorolac as an alternative to meperidine for the treatment of severe musculoskeletal low back pain (LBP). A double blinded prospective trial in a convenience sample of patients G18 years of age presenting to an urban university hospital emergency department (ED) was conducted over a 19-month period. Patients were included if the pain was musculo- skeletal in origin and was severe enough to warrant parenteral analgesics. Patients were randomized to receive 1 mg/kg meperidine intramuscularly (IM) or 60 mg ketorolac IM. Pain intensity was measured pre-administration and at 60 minutes via a 100 mm Visual Analog Scale (VAS). Outcomes measured at 60 minutes were pain intensity decrease (PID), patient satisfaction, rescue analgesia requirement, sedation level, and adverse effects. Clinically significant pain reduction was defined as a PID of at least 13 mm or a reduction in pain of least 30%. 

See All

What's new?

Management of severe musculoskeletal low back pain using ketorolac provides comparable analgesia to meperidine with significantly less sedation and less adverse effects.

Source:

Am J Emerg Med. 2000 Jul_18(4)404-7

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: